Keybank National Association OH Reduces Position in DexCom, Inc. (NASDAQ:DXCM)

Keybank National Association OH cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,333 shares of the medical device company’s stock after selling 252 shares during the quarter. Keybank National Association OH’s holdings in DexCom were worth $1,184,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. DAVENPORT & Co LLC lifted its holdings in shares of DexCom by 17.2% in the first quarter. DAVENPORT & Co LLC now owns 45,136 shares of the medical device company’s stock worth $3,082,000 after buying an additional 6,615 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of DexCom by 1.5% in the first quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 47,984 shares of the medical device company’s stock worth $3,277,000 after buying an additional 721 shares in the last quarter. Kampmann Melissa S. lifted its holdings in shares of DexCom by 13.3% in the first quarter. Kampmann Melissa S. now owns 37,785 shares of the medical device company’s stock worth $2,580,000 after buying an additional 4,450 shares in the last quarter. Mather Group LLC. lifted its holdings in shares of DexCom by 135.5% in the first quarter. Mather Group LLC. now owns 1,109 shares of the medical device company’s stock worth $76,000 after buying an additional 638 shares in the last quarter. Finally, Amalgamated Bank lifted its holdings in shares of DexCom by 2.7% in the first quarter. Amalgamated Bank now owns 83,082 shares of the medical device company’s stock worth $5,674,000 after buying an additional 2,176 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Down 1.0%

Shares of NASDAQ DXCM opened at $82.73 on Friday. DexCom, Inc. has a one year low of $57.52 and a one year high of $117.19. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. The firm’s 50 day simple moving average is $83.26 and its two-hundred day simple moving average is $79.82. The stock has a market capitalization of $32.44 billion, a P/E ratio of 61.74, a PEG ratio of 1.77 and a beta of 1.44.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the previous year, the business earned $0.32 earnings per share. The firm’s revenue was up 12.5% on a year-over-year basis. As a group, analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 6,184 shares of the firm’s stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the transaction, the executive vice president owned 109,621 shares in the company, valued at approximately $9,329,843.31. This trade represents a 5.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael Jon Brown sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $84.28, for a total transaction of $842,800.00. Following the completion of the transaction, the executive vice president owned 95,602 shares in the company, valued at $8,057,336.56. This represents a 9.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 27,190 shares of company stock valued at $2,281,732 over the last ninety days. Insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the topic of a number of recent analyst reports. Robert W. Baird lowered their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Friday, May 2nd. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Cfra Research raised shares of DexCom to a “hold” rating in a research note on Friday, March 21st. Truist Financial began coverage on shares of DexCom in a research note on Monday, June 16th. They issued a “buy” rating and a $102.00 target price on the stock. Finally, Piper Sandler lowered their target price on shares of DexCom from $100.00 to $90.00 and set an “overweight” rating on the stock in a research note on Friday, May 2nd. Five analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $98.50.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.